Cardiovascular Genetic Risk Testing for Targeting Statin Therapy in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Cost-Effectiveness Analysis [Original Articles]

Conclusions:
Testing for a 27-single-nucleotide polymorphism cGRS is generally not a cost-effective approach for targeting statin therapy in the primary prevention of ASCVD for low- to intermediate-risk patients.

Source: Circulation: Cardiovascular Quality and Outcomes - April 12, 2018 Category: Cardiology Authors: Jarmul, J., Pletcher, M. J., Hassmiller Lich, K., Wheeler, S. B., Weinberger, M., Avery, C. L., Jonas, D. E., Earnshaw, S., Pignone, M. Tags: Cardiovascular Disease, Primary Prevention, Risk Factors, Genetics, Cost-Effectiveness Original Articles Source Type: research